ADPKD Clinical Trial - Statin Therapy in Patients With Early Stage ADPKD

Status Active, not recruiting

Clinical Trial Summary

This study plans to learn if pravastatin is helpful in slowing down the progression of kidney disease in adults with autosomal dominant polycystic kidney disease (ADPKD). Pravastatin has been approved by the Food and Drug Administration (FDA) for adults for treatment of hyperlipidemia (high cholesterol levels). The investigators are using pravastatin in this study as an investigational drug for treatment of ADPKD.

Clinical Trial Description

This is a randomized, double-blind, placebo-controlled trial designed to assess the efficacy and benefits of pravastatin therapy in adults with ADPKD by evaluating 1) kidney volume as measured by kidney magnetic resonance imaging (MRI); 2) renal blood flow as measured by kidney magnetic resonance angiography (MRA); 3) kidney function as assessed by Glofil-125; 4) plasma and urine protein markers that will allow a better understanding of how pravastatin works in ADPKD; and 5) blood vessel stiffness as measured by carotid-femoral pulse wave velocity. These parameters will be measured at baseline and after 2 years of pravastatin or placebo treatment in 150 patients with ADPKD. ;

Study Design

Related Conditions & MeSH terms

ADPKD
Autosomal Dominant Polycystic Kidney
Polycystic Kidney Diseases
Polycystic Kidney, Autosomal Dominant

Clinical Trial Details

NCT number	NCT03273413
Study type	Interventional
Source	University of Colorado, Denver
Contact
Status	Active, not recruiting
Phase	Phase 4
Start date	August 31, 2017
Completion date	April 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04310319` - Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt	N/A
Recruiting	`NCT03596957` - Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Disease	Phase 4
Terminated	`NCT04064346` - Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease	Phase 3
Completed	`NCT03203642` - Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD	Phase 2
Recruiting	`NCT05500157` - Assessment of Treatment With Laparoscopic Fenestration or Aspiration Sclerotherapy for Large Symptomatic Hepatic Cysts	N/A
Recruiting	`NCT04111692` - A Prospective Observational Study of Foam Sclerotherapy .
Recruiting	`NCT04907799` - Daily Caloric Restriction in ADPKD	N/A
Completed	`NCT05401409` - Effect of Beetroot Juice on Reducing Hypertension in Autosomal Dominant Polycystic Kidney Disease	N/A
Terminated	`NCT03918447` - A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON	Phase 3
Not yet recruiting	`NCT06391450` - Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD)	Phase 4
Terminated	`NCT03749447` - An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)	Phase 3
Recruiting	`NCT05228574` - Treatment of Vascular Stiffness in ADPKD	Phase 4
Completed	`NCT04908462` - To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy Volunteers	Phase 1
Completed	`NCT03858439` - Dietary Intervention in ADPKD on Tolvaptan	N/A
Recruiting	`NCT05478083` - A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease	Phase 2
Completed	`NCT03102632` - A Clinical Trial of Water Therapy for Autosomal Dominant Polycystic Kidney Disease	N/A
Recruiting	`NCT05996731` - Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases	N/A
Recruiting	`NCT06193616` - Outcome of ADPKD With Octreotide LAR
Completed	`NCT05646420` - Thyroid Hormones in ADPKD	N/A
Completed	`NCT03366337` - A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX	Phase 2